Amphastar Pharmaceuticals AMPH
$28.25 +$0.14 (+0.50%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.26 +0.04%
Open$28.14
Prev close$28.11
Day range$27.79 – $28.70
Volume498.5K
Market cap$1.20B
P/E (TTM)13.0
Dividend yield–
AMPH Stock News
Headlines matching Amphastar Pharmaceuticals or the AMPH ticker, most recent first.
- Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $20 Positive
- Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $20
- Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 Negative
- Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $23 Positive
- Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
- Amphastar Pharmaceuticals (AMPH) Gets a Hold From J.P. Morgan
- Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 Negative
- Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH)
- BofA Securities Downgrades Amphastar Pharmaceuticals(AMPH.US) to Sell Rating, Cuts Target Price to $20 Negative
- Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX)
- Needham Downgrades Amphastar Pharmaceuticals(AMPH.US) to Hold Rating Negative
- Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19
- Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $21 Negative
- Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $23 Negative
- Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $30
No comments yet — be the first to weigh in on AMPH.
Sign in to join the discussion.